Evidence map›Paper›PMID 42440506›Full record

ArticleFrontiers in immunology2026

CD4 T cell phenotype after AS01-adjuvanted immunization is shaped by prior antigen or pathogen exposure.

Robbert G van der Most, Geert Leroux-Roels

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robbert G van der MostVaxxCellence, Antwerp, Belgium.
Geert Leroux-RoelsCenter for Vaccinology (CEVAC), Ghent University and Ghent University Hospital, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD4 T-cell responses are important for the protection conferred by many infectious disease vaccines and can be quantitatively and qualitatively improved by adjuvants. The AS01 adjuvant is present in critical licensed or candidate vaccines against, amongst others, zoster, respiratory syncytial virus, malaria and tuberculosis. During their clinical development, these vaccines have been evaluated in populations ranging from immunologically naïve to strongly pathogen-primed individuals. We dissected the vaccine-induced CD4 T-cell responses across these studies, to elucidate how pre-existing immune memory in the host drives the polyfunctional phenotype of the vaccine-induced CD4 T cells. Across the investigated vaccines, a consistent pattern emerged, in which the capacity of antigen-specific vaccine-induced CD4 T cells to produce interferon-γ appeared to depend on increased levels of prior exposure, leading to pre-existing memory T cells. As the dominant origin of a vaccine-induced CD4 T-cell response (i.e., memory cells with a pre-existing T-cell receptor repertoire, or newly recruited naïve cells) remains to be clarified, this observation helps to guide future research into efficacious next-generation vaccines tailored to the specific immune priming status of the target population.

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineCD4-Positive T-LymphocytesLipid AAnimalsDrug CombinationsHumansImmunizationImmunologic MemoryInterferon-gammaMemory T CellsPhenotypeSaponinsAdjuvants, ImmunologicAdjuvants, Vaccineadjuvant system 01Drug CombinationsInterferon-gammaLipid ASaponinsadjuvantAS01CD4 T cellscytokine expressionhumanIGN-gimmune memoryvaccine

Identifiers

PMID42440506
PMCPMC13333456

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.